Section Lead: Rosemary Mann
The Influenza and Infectious and Emerging Diseases Contracts Section takes a comprehensive approach to developing and acquiring a broad array of medical countermeasures for pandemic flu and other emerging infectious diseases, including vaccines, therapeutics, diagnostics and non-pharmaceutical countermeasures. As part of this approach, the Influenza and Infectious and Emerging Diseases Contracts Section supports activities to sustain these products, including the building and sustaining of their domestic manufacturing infrastructure. It supports the Pandemic Influenza Preparedness Program and Infectious and Emerging Disease Program of the Biomedical Advance Research and Development Authority (BARDA).
The Influenza and Infectious and Emerging Diseases Section generally uses Open Market Competitive acquisitions; although there are some products that are purchased through the General Services Administration Government Wide Acquisition Contracts (GWAC). Acquisitions average $200,000,000 and are usually classified as Research and Development.
Submit a Proposal under the BARDA Broad Agency Announcement Advanced Development of Medical Countermeasures for Pandemic Influenza
- Personal Protective Equipment (Masks and Respirators) for Influenza Infection & All-Hazards
- Full-Featured Continuous Ventilators for Influenza Infection & All-Hazards
- Clinical Influenza Test Systems and Diagnostic Tools
- Influenza Therapeutics
- Influenza Vaccines
A submission in response to this BAA constitutes competition for a contract under an active solicitation issued in accordance with the Federal Acquisition Regulation (FAR 15.306)
. As such, companies cannot meet with BARDA personnel regarding technologies or products related to the submission until review and disposition of the white paper or full proposal. This includes meetings that are requested through MedicalCountermeasures.gov
. However, if you would like to discuss a different concept or idea that you believe fits under the Flu and IED BAA, you may request a meeting with BARDA to discuss this technology.